Exchange: TSX·Updated 04:00 PM EDT

APTX.TSX News

News
all
press releases
Pharma Junior Rallies 66% as Asset Monetization Unlocks $18M Upfront Cash
An upfront cash infusion from a commercial asset sale sparked a massive morning rally in specialty pharma today, highlighting how non-dilutive liquidity events can rapidly re-rate microcap balance sheets. When a developer monetizes its majority stake in an approved drug to a global manufacturing partner, the market quickly rewards the immediate cash injection. RedHill Biopharma Ltd. (Nasdaq: RDHL) advanced Monday after divesting its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for $18M in cash upfront, plus up to additional $35M tied to worldwide net-sales ...
AllPennyStocks.com

Advertisement|Remove ads.